Jeffco-based TriSalus Life Sciences Inc. has appointed Richard Marshall as its chief medical officer on a full-time basis, effective June 29, 2026. He will move into the role from his position as medical director, which he has held since January 2025.
In the new role, Marshall will lead the company’s medical strategy and provide clinical leadership across development and evidence generation, as well as broader strategic initiatives.
“Dr. Marshall brings a rare combination of frontline clinical insight and deep interventional oncology expertise that is uniquely aligned with our mission,” said TriSalus CEO Mary Szela. “As we continue to see strong physician engagement, utilization and interest in the PEDD platform, Dr. Marshall’s appointment as Chief Medical Officer positions us to accelerate the advancement of our clinical and economic advantages data and deliver meaningful impact for patients.”
Marshall is an interventional radiologist with experience in interventional oncology, hepatobiliary interventions, and trauma care.
Marshall said he is honored to step into the chief medical officer role and noted the company is addressing treatment challenges in liver and pancreatic tumors, adding that he looks forward to advancing the company’s medical and clinical efforts.
The company said the appointment reflects its focus on strengthening leadership as it advances its pressure-enabled drug delivery platform and related therapeutic development efforts for patients with solid tumors.
Source: Press Release
